Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE7A | Q13946 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | CES1 | P23141 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.39 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.38 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.36 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.36 |
| ▸ | F2R | P25116 | 1/20 | 0.36 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.36 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | BCHE | P06276 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12640147 | 0.86 | CES2 (0.41) | CES2CES1KDM4ERIPK1CXCR3 | |
| SCHEMBL12824157 | 0.84 | SIGMAR1 (0.46) | CES2CES1KDM4ERIPK1CXCR3 | |
| SCHEMBL1300316 | 0.84 | CNR2 (0.42) | CES2CES1KDM4ERIPK1CXCR3 | |
| SCHEMBL16438490 | 0.84 | RIPK1 (0.42) | CES2CES1KDM4ERIPK1CXCR3 | |
| SCHEMBL15431417 | 0.82 | POLB (0.39) | PDE7APOLBKDM4ERIPK1MTNR1A | |
| SCHEMBL25973151 | 0.82 | RIPK1 (0.41) | CES2CES1KDM4ERIPK1CXCR3 | |
| SCHEMBL23486765 | 0.81 | GABRP (0.42) | PDE7APOLBKDM4ERIPK1ITGB3 | |
| SCHEMBL20327074 | 0.81 | POLB (0.38) | PDE7APOLBKDM4ERIPK1MTNR1A | |
| SCHEMBL20869273 | 0.79 | TDP1 (0.38) | CES2CES1KDM4ERIPK1CXCR3 | |
| SCHEMBL24583660 | 0.79 | POLB (0.45) | PDE7APOLBKDM4EALDH1A1BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018115380-A1 | NOVEL BENZYLAMINO SUBSTITUTED QUINAZOLINES AND DERIVATIVES AS SOS1 INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-06-28 | — | — | WO | disclosed |
| US-7919515-B2 | 3-phenylpropionic acid derivatives | ADAMED SP. Z O.O. (PL) | 2011-04-05 | — | — | US | disclosed |
| EP-1833805-B1 | NEW 3-PHENYLPROPIONIC ACID DERIVATIVES FOR THE TREATMENT OF DIABETES | ADAMED SP ZOO (PL) | 2010-02-10 | — | — | EP | disclosed |
| US-7629370-B2 | 3-phenylpropionic acid derivatives | ADAMED SP. Z O.O. (PL) | 2009-12-08 | — | — | US | disclosed |
| EP-1874745-B1 | NEW 3-PHENYLPROPIONIC ACID DERIVATIVES AND THEIR USE AS PPAR- GAMMA RECEPTOR LIGANDS | ADAMED SP ZOO (PL) | 2009-11-11 | — | — | EP | disclosed |
| EP-1874745-A1 | NEW 3-PHENYLPROPIONIC ACID DERIVATIVES AND THEIR USE AS PPAR- GAMMA RECEPTOR LIGANDS | Adamed SP. Z O.O. (PL) | 2008-01-09 | — | — | EP | disclosed |
| US-7312338-B2 | 3-phenylpropionic acid derivatives | ADAMED, SP. Z.O.O. (PL) | 2007-12-25 | — | — | US | disclosed |
| US-7309791-B2 | 3-phenylpropionic acid derivatives | ADAMED SP. Z.O.O (PL) | 2007-12-18 | — | — | US | disclosed |
| US-20070219259-A1 | NEW 3-PHENYLPROPIONIC ACID DERIVATIVES | ADAMED SP. Z O.O. (PL) | 2007-09-20 | — | — | US | disclosed |
| EP-1833805-A1 | NEW 3-PHENYLPROPIONIC ACID DERIVATIVES FOR THE TREATMENT OF DIABETES | Adamed SP. Z O.O. (PL) | 2007-09-19 | — | — | EP | disclosed |
| US-20070161799-A1 | 3-Phenylpropionic acid derivatives | ADAMED, SP. Z O.O. (PL) | 2007-07-12 | — | — | US | disclosed |
| US-7220766-B2 | 3-phenylpropionic acid derivatives | ADAMED, SP. Z.O.O. (PL) | 2007-05-22 | — | — | US | disclosed |
| US-20070088061-A1 | New 3-phenylpropionic acid derivatives | ADAMED, SP. Z.O.O. (PL) | 2007-04-19 | — | — | US | disclosed |
| WO-2006077206-A1 | NEW 3-PHENYLPROPIONIC ACID DERIVATIVES AND THEIR USE AS PPAR- GAMMA REZEPTOR LIGANDEN | ADAMED SP. Z O.O. (PL) | 2006-07-27 | — | — | WO | disclosed |
| WO-2006077217-A1 | NEW 3-PHENYLPROPIONIC ACID DERIVATIVES | ADAMED SP. Z O.O. (PL) | 2006-07-27 | — | — | WO | disclosed |
| US-20060160870-A1 | 3-phenylpropionic acid derivatives | ADAMED, SP. Z.O.O. (PL) | 2006-07-20 | — | — | US | disclosed |
| US-20060160868-A1 | 3-Phenylpropionic acid derivatives | ADAMED, SP. Z.O.O. (PL) | 2006-07-20 | — | — | US | disclosed |
| WO-2006067086-A1 | NEW 3-PHENYLPROPIONIC ACID DERIVATIVES FOR THE TREATMENT OF DIABETES | ADAMED SP. Z O.O. (PL) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070088061-A1 | New 3-phenylpropionic acid derivatives | PPARA, PPARD, PPARG | PDE7A 1585/4885POLB 2652/4885CES2 1286/4885 |
| US-20070161799-A1 | 3-Phenylpropionic acid derivatives | PAOX, PPARA, PPARG | PDE7A 2347/4885POLB 2070/4885CES2 854/4885 |
| US-20060160870-A1 | 3-phenylpropionic acid derivatives | PPARA, PPARG, PPARD | PDE7A 1454/4885POLB 2438/4885CES2 945/4885 |
| US-20060160868-A1 | 3-Phenylpropionic acid derivatives | PPARA, PPARG, PPARD | PDE7A 2131/4885POLB 2754/4885CES2 1134/4885 |
| US-20070219259-A1 | NEW 3-PHENYLPROPIONIC ACID DERIVATIVES | PPARA, PPARD, PPARG | PDE7A 1580/4885POLB 2626/4885CES2 1198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.